Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.

Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JM Jr, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O'Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network..

N Engl J Med. 2008 Aug 28;359(9):895-905. doi: 10.1056/NEJMoa0801187.

2.

Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.

Crowther CA, Hiller JE, Doyle LW, Haslam RR; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group..

JAMA. 2003 Nov 26;290(20):2669-76.

PMID:
14645308
3.

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis.

Costantine MM, Weiner SJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network..

Obstet Gynecol. 2009 Aug;114(2 Pt 1):354-64. doi: 10.1097/AOG.0b013e3181ae98c2.

4.

Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes.

Horton AL, Lai Y, Rouse DJ, Spong CY, Leveno KJ, Varner MW, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Thorp JM, Ramin SM, Malone FD, O'Sullivan MJ, Hankins GD, Caritis SN; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network..

Am J Perinatol. 2015 Mar;32(4):387-92. doi: 10.1055/s-0034-1387930.

5.

Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.

Crowther CA, Middleton PF, Wilkinson D, Ashwood P, Haslam R; MAGENTA Study Group..

BMC Pregnancy Childbirth. 2013 Apr 9;13:91. doi: 10.1186/1471-2393-13-91.

6.

Maternal obesity and neuroprotective magnesium sulfate.

McPherson J, Smiley S, Stamilio D.

Am J Obstet Gynecol. 2015 Oct;213(4):582.e1-6. doi: 10.1016/j.ajog.2015.06.046.

PMID:
26116874
7.

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo.

Doyle LW, Anderson PJ, Haslam R, Lee KJ, Crowther C; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group..

JAMA. 2014 Sep 17;312(11):1105-13. doi: 10.1001/jama.2014.11189.

PMID:
25226476
8.

Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour.

McNamara HC, Crowther CA, Brown J.

Cochrane Database Syst Rev. 2015 Dec 14;(12):CD011200. doi: 10.1002/14651858.CD011200.pub2. Review.

PMID:
26662716
9.

Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants.

Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, Tomich PG.

Am J Obstet Gynecol. 2002 Jun;186(6):1111-8.

PMID:
12066082
10.

Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes.

McPherson JA, Rouse DJ, Grobman WA, Palatnik A, Stamilio DM.

Obstet Gynecol. 2014 Oct;124(4):749-55. doi: 10.1097/AOG.0000000000000467.

PMID:
25198275
11.

Magnesium sulphate for preventing preterm birth in threatened preterm labour.

Crowther CA, Brown J, McKinlay CJ, Middleton P.

Cochrane Database Syst Rev. 2014 Aug 15;(8):CD001060. doi: 10.1002/14651858.CD001060.pub2. Review.

PMID:
25126773
12.

Magnesium sulfate for the prevention of cerebral palsy.

Mittendorf R, Pryde PG.

N Engl J Med. 2009 Jan 8;360(2):189-90; author reply 190. doi: 10.1056/NEJMc081995. No abstract available.

13.

Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection.

American College of Obstetricians and Gynecologists Committee on Obstetric Practice.; Society for Maternal-Fetal Medicine..

Obstet Gynecol. 2010 Mar;115(3):669-71. doi: 10.1097/AOG.0b013e3181d4ffa5.

PMID:
20177305
14.

In defense of magnesium sulfate.

Elliott JP, Lewis DF, Morrison JC, Garite TJ.

Obstet Gynecol. 2009 Jun;113(6):1341-8. doi: 10.1097/AOG.0b013e3181a71551. Review.

PMID:
19461432
15.

Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years.

Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P.

JAMA. 1996 Dec 11;276(22):1805-10.

PMID:
8946900
16.

The feasibility of a randomized clinical perinatal trial: maternal magnesium sulfate for the prevention of cerebral palsy.

Rouse DJ, Hauth JC, Nelson KG, Goldenberg RL.

Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):701-5.

PMID:
8828437
17.

Antenatal magnesium sulfate for neuroprotection before preterm birth?

Stanley FJ, Crowther C.

N Engl J Med. 2008 Aug 28;359(9):962-4. doi: 10.1056/NEJMe0805018. No abstract available.

PMID:
18753653
18.

Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.

Conde-Agudelo A, Romero R.

Am J Obstet Gynecol. 2009 Jun;200(6):595-609. doi: 10.1016/j.ajog.2009.04.005. Review.

19.

Magnesium sulphate for preventing preterm birth in threatened preterm labour.

Crowther CA, Hiller JE, Doyle LW.

Cochrane Database Syst Rev. 2002;(4):CD001060. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD001060.

PMID:
12519550
20.

Magnesium sulfate for cerebral palsy prevention.

Rouse DJ, Gibbins KJ.

Semin Perinatol. 2013 Dec;37(6):414-6. doi: 10.1053/j.semperi.2013.06.025.

PMID:
24290398

Supplemental Content

Support Center